Published in Rev Endocr Metab Disord on March 01, 2010
Restenosis after PCI. Part 1: pathophysiology and risk factors. Nat Rev Cardiol (2011) 1.32
Coronary artery revascularization in patients with diabetes mellitus. Circulation (2013) 0.89
Influence of obesity and metabolic dysfunction on the endothelial control in the coronary circulation. J Mol Cell Cardiol (2011) 0.87
Peripheral artery disease in patients with diabetes: Epidemiology, mechanisms, and outcomes. World J Diabetes (2015) 0.84
Shen-Fu injection preconditioning inhibits myocardial ischemia-reperfusion injury in diabetic rats: activation of eNOS via the PI3K/Akt pathway. J Biomed Biotechnol (2010) 0.82
Percutaneous coronary intervention in patients with diabetes: current concepts and future directions. J Diabetes Sci Technol (2014) 0.81
Troponin in diabetic patients with and without chronic coronary artery disease. BMC Cardiovasc Disord (2015) 0.77
Coronary artery disease and diabetes mellitus. Cardiol Clin (2014) 0.76
Editorial on the original article entitled "Changes in diabetes-related complications in the United States, 1990-2010" published in the New England Journal of Medicine on April 17, 2014. Ann Transl Med (2014) 0.75
Role of CABG in the management of obstructive coronary arterial disease in patients with diabetes mellitus. Curr Opin Pharmacol (2012) 0.75
The role of endothelial nitric oxide in the anti-restenotic effects of liraglutide in a mouse model of restenosis. Cardiovasc Diabetol (2017) 0.75
Functional differences between healthy and diabetic endothelial cells on topographical cues. Biomaterials (2017) 0.75
Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med (2008) 47.90
Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med (1998) 25.66
Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med (2007) 25.17
A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med (2009) 12.15
Clinical end points in coronary stent trials: a case for standardized definitions. Circulation (2007) 10.31
Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA (2005) 9.81
Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet (2007) 7.61
Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet (2007) 6.77
Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. The Bypass Angioplasty Revascularization Investigation (BARI) Investigators. N Engl J Med (1996) 6.70
Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. Circulation (2002) 6.26
Paclitaxel-eluting or sirolimus-eluting stents to prevent restenosis in diabetic patients. N Engl J Med (2005) 3.75
A hierarchical Bayesian meta-analysis of randomised clinical trials of drug-eluting stents. Lancet (2004) 3.52
Drug-eluting stent and coronary thrombosis: biological mechanisms and clinical implications. Circulation (2007) 2.93
Percutaneous coronary interventions for non-acute coronary artery disease: a quantitative 20-year synopsis and a network meta-analysis. Lancet (2009) 2.81
Five-year outcomes after coronary stenting versus bypass surgery for the treatment of multivessel disease: the final analysis of the Arterial Revascularization Therapies Study (ARTS) randomized trial. J Am Coll Cardiol (2005) 2.50
Mechanisms of Disease: endothelial dysfunction in insulin resistance and diabetes. Nat Clin Pract Endocrinol Metab (2007) 2.48
Central role of RAGE-dependent neointimal expansion in arterial restenosis. J Clin Invest (2003) 2.40
Influence of diabetes on 5-year mortality and morbidity in a randomized trial comparing CABG and PTCA in patients with multivessel disease: the Bypass Angioplasty Revascularization Investigation (BARI) Circulation (1997) 2.34
Clinical and economic impact of diabetes mellitus on percutaneous and surgical treatment of multivessel coronary disease patients: insights from the Arterial Revascularization Therapy Study (ARTS) trial. Circulation (2001) 2.28
Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: Part II. Circulation (2003) 2.28
Diabetic and nondiabetic patients with left main and/or 3-vessel coronary artery disease: comparison of outcomes with cardiac surgery and paclitaxel-eluting stents. J Am Coll Cardiol (2010) 2.24
Coronary angioplasty in diabetic patients. The National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry. Circulation (1996) 2.19
Overexpression of fibronectin induced by diabetes or high glucose: phenomenon with a memory. Proc Natl Acad Sci U S A (1990) 2.18
Optimal glycemic control is associated with a lower rate of target vessel revascularization in treated type II diabetic patients undergoing elective percutaneous coronary intervention. J Am Coll Cardiol (2004) 2.14
The effect of previous coronary-artery bypass surgery on the prognosis of patients with diabetes who have acute myocardial infarction. Bypass Angioplasty Revascularization Investigation Investigators. N Engl J Med (2000) 2.11
Drug eluting and bare metal stents in people with and without diabetes: collaborative network meta-analysis. BMJ (2008) 2.09
The influence of diabetes mellitus on acute and late clinical outcomes following coronary stent implantation. J Am Coll Cardiol (1998) 1.91
Early stent thrombosis in patients with acute coronary syndromes treated with drug-eluting and bare metal stents: the Acute Catheterization and Urgent Intervention Triage Strategy trial. Circulation (2009) 1.88
Preventative effects of rosiglitazone on restenosis after coronary stent implantation in patients with type 2 diabetes. Diabetes Care (2004) 1.84
Predictive factors of restenosis after coronary stent placement. J Am Coll Cardiol (1997) 1.84
Incidence and correlates of drug-eluting stent thrombosis in routine clinical practice. 4-year results from a large 2-institutional cohort study. J Am Coll Cardiol (2008) 1.84
Impact of sirolimus-eluting stents on outcome in diabetic patients: a SIRIUS (SIRolImUS-coated Bx Velocity balloon-expandable stent in the treatment of patients with de novo coronary artery lesions) substudy. Circulation (2004) 1.83
Restenosis rates in diabetic patients: a comparison of coronary stenting and balloon angioplasty in native coronary vessels. Circulation (1997) 1.80
Eight-year mortality in the Emory Angioplasty versus Surgery Trial (EAST) J Am Coll Cardiol (2000) 1.79
The insulin-like growth factor axis: A review of atherosclerosis and restenosis. Circ Res (2000) 1.75
Diabetes mellitus and the clinical and angiographic outcome after coronary stent placement. J Am Coll Cardiol (1998) 1.73
The final 10-year follow-up results from the BARI randomized trial. J Am Coll Cardiol (2007) 1.68
Influence of diabetes mellitus on early and late outcome after percutaneous transluminal coronary angioplasty. Circulation (1995) 1.66
Five-year angiographic follow-up of factors associated with progression of coronary artery disease in the Coronary Artery Surgery Study (CASS). CASS Participating Investigators and Staff. J Am Coll Cardiol (1993) 1.66
Diabetes-induced oxidative stress and low-grade inflammation in porcine coronary arteries. Circulation (2003) 1.65
The platelet in diabetes: focus on prevention of ischemic events. Diabetes Care (2003) 1.63
Association of insulin resistance, hyperleptinemia, and impaired nitric oxide release with in-stent restenosis in patients undergoing coronary stenting. Circulation (2003) 1.63
Clinical restenosis after coronary stenting: perspectives from multicenter clinical trials. J Am Coll Cardiol (2002) 1.62
Outcomes with the polymer-based paclitaxel-eluting TAXUS stent in patients with diabetes mellitus: the TAXUS-IV trial. J Am Coll Cardiol (2005) 1.59
Safety and efficacy of drug-eluting vs. bare metal stents in patients with diabetes mellitus: long-term follow-up in the Swedish Coronary Angiography and Angioplasty Registry (SCAAR). Eur Heart J (2009) 1.55
Late coronary stent thrombosis. Circulation (2007) 1.54
Diabetes mellitus and outcome after primary coronary angioplasty for acute myocardial infarction: lessons from the GUSTO-IIb Angioplasty Substudy. Global Use of Strategies to Open Occluded Arteries in Acute Coronary Syndromes. J Am Coll Cardiol (2000) 1.53
Randomized comparison of percutaneous coronary intervention with coronary artery bypass grafting in diabetic patients. 1-year results of the CARDia (Coronary Artery Revascularization in Diabetes) trial. J Am Coll Cardiol (2010) 1.51
Diabetes and coronary revascularization. JAMA (2005) 1.45
Pioglitazone reduces neointima volume after coronary stent implantation: a randomized, placebo-controlled, double-blind trial in nondiabetic patients. Circulation (2005) 1.42
Randomized comparison of sirolimus-eluting stent versus standard stent for percutaneous coronary revascularization in diabetic patients: the diabetes and sirolimus-eluting stent (DIABETES) trial. Circulation (2005) 1.38
Restenosis after percutaneous transluminal coronary angioplasty (PTCA): a report from the PTCA Registry of the National Heart, Lung, and Blood Institute. Am J Cardiol (1984) 1.36
Increased restenosis in diabetes mellitus after coronary interventions is due to exaggerated intimal hyperplasia. A serial intravascular ultrasound study. Circulation (1997) 1.35
The comparative pathobiology of atherosclerosis and restenosis. Am J Cardiol (2000) 1.33
Vascular neointimal formation and signaling pathway activation in response to stent injury in insulin-resistant and diabetic animals. Circ Res (2005) 1.32
Safety of coronary sirolimus-eluting stents in daily clinical practice: one-year follow-up of the e-Cypher registry. Circulation (2006) 1.28
Stent thrombosis in Sweden: a report from the Swedish Coronary Angiography and Angioplasty Registry. Circ Cardiovasc Interv (2009) 1.25
Coronary heart disease in patients with diabetes: part II: recent advances in coronary revascularization. J Am Coll Cardiol (2007) 1.23
Mechanisms determining course and outcome of diabetic patients who have had acute myocardial infarction. Ann Intern Med (1997) 1.23
Coronary heart disease in patients with diabetes: part I: recent advances in prevention and noninvasive management. J Am Coll Cardiol (2007) 1.22
Potential mechanisms promoting restenosis in diabetic patients. J Am Coll Cardiol (1996) 1.15
Clinical and angiographic predictors of restenosis after stent deployment in diabetic patients. Circulation (2004) 1.13
Neutrophil, not macrophage, infiltration precedes neointimal thickening in balloon-injured arteries. Arterioscler Thromb Vasc Biol (2000) 1.12
Diabetes with coronary disease--a moving target amid evolving therapies? N Engl J Med (2009) 1.12
Design of the Future REvascularization Evaluation in patients with Diabetes mellitus: Optimal management of Multivessel disease (FREEDOM) Trial. Am Heart J (2008) 1.11
Glucose modulates basement membrane fibroblast growth factor-2 via alterations in endothelial cell permeability. J Biol Chem (2007) 1.05
Multivessel coronary revascularization in patients with and without diabetes mellitus: 3-year follow-up of the ARTS-II (Arterial Revascularization Therapies Study-Part II) trial. J Am Coll Cardiol (2008) 1.05
Troglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with non-insulin dependent diabetes mellitus: a serial intravascular ultrasound study. J Am Coll Cardiol (2000) 1.04
Coronary bypass graft patency in patients with diabetes in the Bypass Angioplasty Revascularization Investigation (BARI). Circulation (2002) 1.03
Risk factors for stent thrombosis after implantation of sirolimus-eluting stents in diabetic and nondiabetic patients: the EVASTENT Matched-Cohort Registry. J Am Coll Cardiol (2007) 1.03
Restenosis after arterial injury caused by coronary stenting in patients with diabetes mellitus. Ann Intern Med (1993) 1.02
Interlesion dependence of the risk for restenosis in patients with coronary stent placement in in multiple lesions. Circulation (1998) 1.01
Influence of treatment modality on angiographic outcome after coronary stenting in diabetic patients: a controlled study. J Am Coll Cardiol (2000) 1.00
Can restenosis after coronary angioplasty be predicted from clinical variables? J Am Coll Cardiol (1993) 0.94
Blockade of endogenous cytokines mitigates neointimal formation in obese Zucker rats. Circulation (2005) 0.94
Effects of aggressive cholesterol lowering and low-dose anticoagulation on clinical and angiographic outcomes in patients with diabetes: the Post Coronary Artery Bypass Graft Trial. Diabetes (1999) 0.92
Percutaneous coronary interventions with drug eluting stents for diabetic patients. Heart (2006) 0.90
Repeat percutaneous transluminal coronary angioplasty and predictors of recurrent restenosis. Am J Cardiol (1989) 0.88
Late stent thrombosis after drug-eluting stent implantation for acute myocardial infarction: a new red flag is raised. Circulation (2008) 0.87
Is surgery preferred for the diabetic with multivessel disease? Surgery is preferred for the diabetic with multivessel disease. Circulation (2005) 0.86
Neointimal hyperplasia after sirolimus-eluting and paclitaxel-eluting stent implantation in diabetic patients: the Randomized Diabetes and Drug-Eluting Stent (DiabeDES) Intravascular Ultrasound Trial. Eur Heart J (2008) 0.85
Multilesion coronary angioplasty: clinical and angiographic follow-up. J Am Coll Cardiol (1987) 0.83
Clinical studies on coronary revascularization in patients with type 2 diabetes. Eur Heart J (2003) 0.83
Potential role of advanced glycosylation end products in promoting restenosis in diabetes and renal failure. Med Hypotheses (2002) 0.83
Bypass surgery versus coronary angioplasty for revascularization of treated diabetic patients. Circulation (1997) 0.83
Enhanced secretion of insulin plays a role in the development of atherosclerosis and restenosis of coronary arteries: elective percutaneous transluminal coronary angioplasty in patients with effort angina. J Am Coll Cardiol (1998) 0.82
Marked improvements in outcomes of contemporary percutaneous coronary intervention in patients with diabetes mellitus. J Interv Cardiol (2006) 0.81
Therapy insight: diabetes and drug-eluting stents. Nat Clin Pract Cardiovasc Med (2007) 0.80
Restenosis, late vessel occlusion and left ventricular function six months after balloon angioplasty in diabetic patients. J Am Coll Cardiol (1999) 0.79
Impact of diabetes mellitus on percutaneous revascularization (CAVEAT-I). CAVEAT-I Investigators. Coronary Angioplasty Versus Excisional Atherectomy Trial. Am J Cardiol (1997) 0.78
The interventional cardiologist and the diabetic patient. Have we pushed the envelope too far or not far enough? Circulation (1996) 0.77
Differential influence of diabetes mellitus on increased jeopardized myocardium after initial angioplasty or bypass surgery: bypass angioplasty revascularization investigation. Circulation (2002) 0.76
Efficacy of a device to narrow the coronary sinus in refractory angina. N Engl J Med (2015) 5.36
Role of endothelial shear stress in the natural history of coronary atherosclerosis and vascular remodeling: molecular, cellular, and vascular behavior. J Am Coll Cardiol (2007) 4.62
Stent thrombogenicity early in high-risk interventional settings is driven by stent design and deployment and protected by polymer-drug coatings. Circulation (2011) 3.16
Kruppel-like factor 4 regulates endothelial inflammation. J Biol Chem (2007) 3.06
Luminal flow patterns dictate arterial drug deposition in stent-based delivery. J Control Release (2008) 1.90
Tissue engineering therapy for cardiovascular disease. Circ Res (2003) 1.87
Prediction of the localization of high-risk coronary atherosclerotic plaques on the basis of low endothelial shear stress: an intravascular ultrasound and histopathology natural history study. Circulation (2008) 1.74
Increased thrombosis after arterial injury in human C-reactive protein-transgenic mice. Circulation (2003) 1.72
Uremic serum and solutes increase post-vascular interventional thrombotic risk through altered stability of smooth muscle cell tissue factor. Circulation (2012) 1.70
Heparanase alters arterial structure, mechanics, and repair following endovascular stenting in mice. Circ Res (2008) 1.64
Stromal endothelial cells directly influence cancer progression. Sci Transl Med (2011) 1.46
In vivo and in vitro tracking of erosion in biodegradable materials using non-invasive fluorescence imaging. Nat Mater (2011) 1.46
Drug-eluting stents in preclinical studies: recommended evaluation from a consensus group. Circulation (2002) 1.45
Ultrasound-guided percutaneous delivery of tissue-engineered endothelial cells to the adventitia of stented arteries controls the response to vascular injury in a porcine model. J Vasc Surg (2012) 1.42
Specific binding to intracellular proteins determines arterial transport properties for rapamycin and paclitaxel. Proc Natl Acad Sci U S A (2004) 1.32
Vascular neointimal formation and signaling pathway activation in response to stent injury in insulin-resistant and diabetic animals. Circ Res (2005) 1.32
Aldehyde-amine chemistry enables modulated biosealants with tissue-specific adhesion. Adv Mater (2009) 1.31
Intravascular drug release kinetics dictate arterial drug deposition, retention, and distribution. J Control Release (2007) 1.29
Enhanced T-helper-1 lymphocyte activation patterns in acute coronary syndromes. J Am Coll Cardiol (2005) 1.27
Strut position, blood flow, and drug deposition: implications for single and overlapping drug-eluting stents. Circulation (2005) 1.26
Natural history of experimental coronary atherosclerosis and vascular remodeling in relation to endothelial shear stress: a serial, in vivo intravascular ultrasound study. Circulation (2010) 1.19
Vascular bed origin dictates flow pattern regulation of endothelial adhesion molecule expression. Am J Physiol Heart Circ Physiol (2007) 1.18
Characterization of star adhesive sealants based on PEG/dextran hydrogels. Macromol Biosci (2009) 1.18
Luminal flow amplifies stent-based drug deposition in arterial bifurcations. PLoS One (2009) 1.17
Perivascular endothelial implants inhibit intimal hyperplasia in a model of arteriovenous fistulae: a safety and efficacy study in the pig. J Vasc Res (2003) 1.12
Endothelial cells provide feedback control for vascular remodeling through a mechanosensitive autocrine TGF-beta signaling pathway. Circ Res (2008) 1.11
Arterial ultrastructure influences transport of locally delivered drugs. Circ Res (2002) 1.11
Augmented expression and activity of extracellular matrix-degrading enzymes in regions of low endothelial shear stress colocalize with coronary atheromata with thin fibrous caps in pigs. Circulation (2011) 1.11
Systemic inflammation induced by lipopolysaccharide increases neointimal formation after balloon and stent injury in rabbits. Circulation (2002) 1.11
Rapamycin for cardiac transplant rejection and vasculopathy: one stone, two birds? Circulation (2003) 1.06
Glucose modulates basement membrane fibroblast growth factor-2 via alterations in endothelial cell permeability. J Biol Chem (2007) 1.05
Cardiology is flow. Circulation (2006) 1.04
Adventitial endothelial implants reduce matrix metalloproteinase-2 expression and increase luminal diameter in porcine arteriovenous grafts. J Vasc Surg (2007) 1.04
Liposomal alendronate inhibits systemic innate immunity and reduces in-stent neointimal hyperplasia in rabbits. Circulation (2003) 1.03
Impact of transport and drug properties on the local pharmacology of drug-eluting stents. Int J Cardiovasc Intervent (2003) 1.02
Dynamic flow alterations dictate leukocyte adhesion and response to endovascular interventions. J Clin Invest (2004) 1.02
Matrix embedding alters the immune response against endothelial cells in vitro and in vivo. Circulation (2005) 1.02
Lesion complexity determines arterial drug distribution after local drug delivery. J Control Release (2009) 1.00
Smooth muscle cells orchestrate the endothelial cell response to flow and injury. Circulation (2010) 1.00
The role of low endothelial shear stress in the conversion of atherosclerotic lesions from stable to unstable plaque. Curr Opin Cardiol (2009) 0.98
Dysfunctional endothelial cells directly stimulate cancer inflammation and metastasis. Int J Cancer (2013) 0.98
Thrombosis modulates arterial drug distribution for drug-eluting stents. Circulation (2005) 0.98
Viscoelastic adhesive mechanics of aldehyde-mediated soft tissue sealants. Biomaterials (2008) 0.97
Natural tissue microenvironmental conditions modulate adhesive material performance. Langmuir (2012) 0.97
Regulation of endothelial cell proliferation by primary monocytes. Arterioscler Thromb Vasc Biol (2007) 0.96
Tissue-engineered endothelial and epithelial implants differentially and synergistically regulate airway repair. Proc Natl Acad Sci U S A (2008) 0.96
Thrombus causes fluctuations in arterial drug delivery from intravascular stents. J Control Release (2008) 0.95
Matrix adherence of endothelial cells attenuates immune reactivity: induction of hyporesponsiveness in allo- and xenogeneic models. FASEB J (2007) 0.94
Syndecan-4 proteoliposomes enhance fibroblast growth factor-2 (FGF-2)-induced proliferation, migration, and neovascularization of ischemic muscle. Proc Natl Acad Sci U S A (2012) 0.94
Role of fluid dynamics and inflammation in intracranial aneurysm formation. Circulation (2014) 0.93
Attenuation of inflammation and expansive remodeling by Valsartan alone or in combination with Simvastatin in high-risk coronary atherosclerotic plaques. Atherosclerosis (2008) 0.93
Preclinical evaluation of drug-eluting stents for peripheral applications: recommendations from an expert consensus group. Circulation (2004) 0.93
Cells in fluidic environments are sensitive to flow frequency. J Cell Physiol (2005) 0.92
Endothelial immunogenicity--a matter of matrix microarchitecture. Thromb Haemost (2007) 0.91
Endothelial cell-matrix interactions determine maturation of dendritic cells. Eur J Immunol (2007) 0.90
The evolution of endothelial regulatory paradigms in cancer biology and vascular repair. Cancer Res (2011) 0.90
Transgenic expression of human C-reactive protein suppresses endothelial nitric oxide synthase expression and bioactivity after vascular injury. Am J Physiol Heart Circ Physiol (2007) 0.90
Quasi-steady-state kinetics at enzyme and substrate concentrations in excess of the Michaelis-Menten constant. J Theor Biol (2006) 0.90
Cell-matrix contact prevents recognition and damage of endothelial cells in states of heightened immunity. Circulation (2006) 0.90
Leukocyte recruitment and expression of chemokines following different forms of vascular injury. Vasc Med (2003) 0.90
Regulation of heparanase expression in coronary artery disease in diabetic, hyperlipidemic swine. Atherosclerosis (2010) 0.89
The effect of three-dimensional matrix-embedding of endothelial cells on the humoral and cellular immune response. Semin Immunol (2008) 0.89
Analysis of compartmental models of ligand-induced endocytosis. J Theor Biol (2004) 0.89
Endosomal receptor kinetics determine the stability of intracellular growth factor signalling complexes. Biochem J (2007) 0.88
Embolic protection with filtering or occlusion balloons during saphenous vein graft stenting retrieves identical volumes and sizes of particulate debris. Circulation (2004) 0.87
Anti-atherosclerotic therapy based on botanicals. Recent Pat Cardiovasc Drug Discov (2013) 0.87
Low background, pulsatile, in vitro flow circuit for modeling coronary implant thrombosis. J Biomech Eng (2002) 0.87
A structural model that explains the effects of hyperglycemia on collagenolysis. Biophys J (2003) 0.87
Augmentation of postswelling surgical sealant potential of adhesive hydrogels. J Biomed Mater Res A (2010) 0.86
Phosphorylation-induced conformational changes in a mitogen-activated protein kinase substrate. Implications for tyrosine hydroxylase activation. J Biol Chem (2002) 0.86
Proangiogenic stimulation of bone marrow endothelium engages mTOR and is inhibited by simultaneous blockade of mTOR and NF-kappaB. Blood (2005) 0.86
Effect of pre-adsorbed proteins on attachment, proliferation, and function of endothelial cells. J Cell Physiol (2002) 0.86
Acute rejection in vascularized composite allotransplantation. Curr Opin Organ Transplant (2014) 0.86
Heparanase regulates thrombosis in vascular injury and stent-induced flow disturbance. J Am Coll Cardiol (2012) 0.86
Mechanisms of tissue uptake and retention in zotarolimus-coated balloon therapy. Circulation (2013) 0.85
The effect of substrate modulus on the growth and function of matrix-embedded endothelial cells. Biomaterials (2012) 0.85
Pushing drug-eluting stents into uncharted territory: simpler than you think--more complex than you imagine. Circulation (2006) 0.85
Environmental influences on endovascular stent platelet reactivity: an in vitro comparison of stainless steel and gold surfaces. J Biomed Mater Res A (2004) 0.85
Local and systemic drug competition in drug-eluting stent tissue deposition properties. J Control Release (2005) 0.85
Impact of flow pulsatility on arterial drug distribution in stent-based therapy. J Control Release (2013) 0.85
Tubular bridges for bronchial epithelial cell migration and communication. PLoS One (2010) 0.85
Thin-capped atheromata with reduced collagen content in pigs develop in coronary arterial regions exposed to persistently low endothelial shear stress. Arterioscler Thromb Vasc Biol (2013) 0.85
Collagen fragments modulate innate immunity. Exp Biol Med (Maywood) (2007) 0.84
The role of scaffold microarchitecture in engineering endothelial cell immunomodulation. Biomaterials (2012) 0.84
Stent elution rate determines drug deposition and receptor-mediated effects. J Control Release (2012) 0.84
C-reactive protein promotes monocyte-platelet aggregation: an additional link to the inflammatory-thrombotic intricacy. Eur J Haematol (2007) 0.84
Primary monocytes regulate endothelial cell survival through secretion of angiopoietin-1 and activation of endothelial Tie2. Arterioscler Thromb Vasc Biol (2011) 0.84
Cellular bridges: Routes for intercellular communication and cell migration. Commun Integr Biol (2010) 0.84
Engineered arterial models to correlate blood flow to tissue biological response. Ann N Y Acad Sci (2012) 0.83
Delivery site of perivascular endothelial cell matrices determines control of stenosis in a porcine femoral stent model. J Vasc Interv Radiol (2009) 0.83
Neointimal formation is reduced after arterial injury in human crp transgenic mice. Atherosclerosis (2008) 0.83
Assessment of material by-product fate from bioresorbable vascular scaffolds. Ann Biomed Eng (2011) 0.83
On the validity of the quasi-steady state approximation of bimolecular reactions in solution. J Theor Biol (2005) 0.83
Optimal control of blood glucose: the diabetic patient or the machine? Sci Transl Med (2010) 0.83
Monocyte activation state regulates monocyte-induced endothelial proliferation through Met signaling. Blood (2010) 0.83
Risk stratification of individual coronary lesions using local endothelial shear stress: a new paradigm for managing coronary artery disease. Curr Opin Cardiol (2007) 0.82
NF-kappaB activity in endothelial cells is modulated by cell substratum interactions and influences chemokine-mediated adhesion of natural killer cells. Cell Transplant (2009) 0.82
Pheochromocytoma-induced cardiomyopathy is modulated by the synergistic effects of cell-secreted factors. Circ Heart Fail (2009) 0.81
High concentrations of drug in target tissues following local controlled release are utilized for both drug distribution and biologic effect: an example with epicardial inotropic drug delivery. J Control Release (2013) 0.81
Intramuscular drug transport under mechanical loading: resonance between tissue function and uptake. J Control Release (2009) 0.81